The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Drug Eluting Stent Market Progress Between 2026 And 2030?

The drug eluting stent market has demonstrated robust growth in recent years. It is expected to expand from $8.26 billion in 2025 to $8.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.2%. This historical development can be linked to factors such as the increasing prevalence of coronary artery disease, a rise in percutaneous coronary intervention procedures, the growing incidence of lifestyle-related cardiovascular conditions, the expansion of cardiac catheterization labs, and enhanced clinical outcomes when compared to bare-metal stents.

The drug eluting stent market size is projected to experience substantial expansion over the upcoming years. It is predicted to reach $11.7 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.9%. The expansion during the forecast timeframe can be attributed to an increasing aging population, a heightened demand for minimally invasive cardiac treatments, growing awareness of advanced stent technologies, the proliferation of specialty cardiac clinics, and elevated healthcare expenditure on cardiovascular care. Major trends anticipated in this period include a greater uptake of biodegradable polymer stents, a developing preference for polymer-free drug-eluting stents, their expanded application in complex coronary interventions, a movement towards long-term restenosis prevention, and a rising requirement for improved drug release control.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15557&type=smp

What Key Factors Are Shaping The Drug Eluting Stent Market Landscape?

The increasing prevalence of coronary heart disease is anticipated to drive the expansion of the drug-eluting stent market in the future. Coronary heart disease (CHD) refers to a condition characterized by the narrowing or obstruction of coronary arteries due to plaque accumulation, which can result in serious issues like heart attacks or angina. Factors contributing to the rise in coronary heart disease include inactive lifestyles, unhealthy eating habits, an aging demographic, and increased diagnostic awareness. Drug-eluting stents (DES) offer advantages in managing coronary heart disease by efficiently opening constricted or blocked coronary arteries and delivering drugs that inhibit the re-narrowing (restenosis) of the artery. An illustrative example, cited in August 2025 by the National Center for Biotechnology Information, a US-based governmental agency, indicates that cardiovascular disease is expected to see a substantial increase between 2025 and 2050. During this period, prevalence is forecast to climb by 90.0%, crude mortality by 73.4%, and crude DALYs by 54.7%. This rise is predicted to result in approximately 35.6 million cardiovascular deaths in 2050, an increase from 20.5 million in 2025. Consequently, the growing burden of coronary heart disease is set to further boost the drug-eluting stench market.

What Are The Key Segment Divisions In The Drug Eluting Stent Market Segment Structure?

The drug eluting stent market covered in this report is segmented –

1) By Product: Polymer-Based, Polymer-Free

2) By Drug: Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, Other Drugs

3) By Scaffold: Cobalt-Chromium, Platinum-Chromium, Nitinol, Biodegradable, Other Scaffolds

4) By Application: Coronary Diseases, Peripheral Vascular Diseases

5) By End-User: Hospitals, Specialty Clinics

Subsegments:

1) By Polymer-Based: Durable Polymer Drug-Eluting Stents, Biodegradable Polymer Drug-Eluting Stents

2) By Polymer-Free: Bare-Metal Stents With Drug Coating, Other Polymer-Free Drug-Eluting Stents

What Market Trends Are Affecting The Drug Eluting Stent Market?

Leading firms in the drug eluting stent sector are prioritizing the creation of advanced products like low-profile, high-flexibility stents, aiming to boost deliverability within intricate coronary anatomies and elevate patient results. Such a stent is characterized by a minimized crossing profile and increased flexibility, enabling simpler navigation through constricted, winding, or calcified coronary arteries, all while ensuring consistent drug delivery to deter restenosis. An illustration of this is Abbott Laboratories, a global healthcare company from the U.S., introducing the XIENCE Sierra Everolimus Eluting Coronary Stent System to India in May 2024. The XIENCE Sierra boasts an innovative stent architecture that provides top-tier deliverability, notably lowering crossing force compared to competing products. Additionally, it incorporates a slimmer balloon and an improved MULTI LINK structure for greater flexibility, complemented by high longitudinal strength that guarantees scaffold stability and resilience against deformation. Furthermore, its broad expansion capacity facilitates precise treatment, even when vessel diameters vary considerably across the lesion, empowering interventional cardiologists to address intricate, calcified, or hard-to-access lesions with enhanced accuracy and safety.

Which Organizations Are Engaged In The Drug Eluting Stent Market?

Major companies operating in the drug eluting stent market are Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Terumo Corporation, BIOTRONIK SE & Co KG, Biosensors International Group Ltd, MicroPort Scientific Corporation, Lepu Medical Technology Beijing Co Ltd, Meril Life Sciences Pvt Ltd, Sahajanand Medical Technologies Pvt Ltd, Alvimedica Medical Technologies, Balton Sp z oo, Cordis (Cardinal Health) DES Manufacturing, Shandong JW Medical Systems Ltd, Sino Medical Sciences Technology Inc, STENTYS SA, Relisys Medical Devices Ltd, Translumina GmbH, Eurocor GmbH, Elixir Medical Corporation

Get The Full Drug Eluting Stent Market Report:

https://www.thebusinessresearchcompany.com/report/drug-eluting-stent-global-market-report

Which Region Is The Top Contributor To The Drug Eluting Stent Market By Share?

North America was the largest region in the drug-eluting stent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Drug Eluting Stent Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/customise?id=15557&type=smp

Browse Through More Reports Similar to the Global Drug Eluting Stent Market 2026, By The Business Research Company

Vascular Stent Market Report 2026

https://www.thebusinessresearchcompany.com/report/vascular-stent-global-market-report

Bioabsorbable Stents Market Report 2026

https://www.thebusinessresearchcompany.com/report/bioabsorbable-stents-global-market-report

Self Expanding Stents Market Report 2026

https://www.thebusinessresearchcompany.com/report/self-expanding-stents-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.